Abstract
Multiple myeloma represents a malignant proliferation of a plasma cells clone. The tumor itself, its metabolic products and the host response account for the clinical manifestations represented in bone involvement, susceptibility to infections, renal failure, anemia, hypercalcemia and several neurological symptoms. The symptoms in the central nervous system are related to plasmocytoma, leptomeningeal myelomatosis and hyperviscosity syndrome.
The manifestations in the peripheral nervous system are represented by low back pain associated to vertebral fractures and radiculopathy. It has been also described in this group the motor and sensitive involvement that results from muscle and peripheral nervous affectation and from multiple phenomenons such as metabolic disturbances, pharmacological treatments and opportunistic infections.
Another explanation for the neuromuscular involvement is related to immunological factors of the disease producing antibodies against structural components, generating the clinical manifestations.
We report a case which neurological manifestations lead to the multiple myeloma diagnosis, with mononeuritis multiplex and myopathy, unusual findings in this entity. We consider the immun etiology as the causative factor of clinical manifestations.
References
Kelly JJ, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31:1480-1483.
Simmons Z. Paraproteinemia and neuropathy. Curr Opin Neurol 1999;12: 589-95.
Pahwa P, McDuffie HH, Dosman JA, Robson D, McLaughlin JR, Spinelli JJ, Fincham S. Exposure to animals and selected risk factors among Canadian farm residents with Hodgkin’s disease, multiple myeloma, or soft tissue sarcoma. J Occup Environ Med 2003; 45: 857-68.
Collins JJ, Ireland B, Buckley CF, Shepperly D. Lymphohaematopoietic cancer mortality among workers with benzene exposure. J Occup Environ Med 2003; 60:676-9.
Kyle RA. Multiple Myeloma: An Overview in 1996. Oncologist 1996;1:315-323.
Pollard JD, Young GAR. Neurology and the bone marrow, J Neurol Neurosurg Psychiatry 1997; 63: 706-718.
Gab DJ, Ssusman JD. Neurological manifestations of haematological disorders. In: Aminoff MJ. Neurology and general Medicine. Churchill livingstone. 2001: 201-231.
Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Eng J Med 1998; 338: 1601-1607.
Garcia-Sanz R, González-Fraile MI, Sierra M, López C, González M, San Miguel JF. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 2002; 3: 43-8.
Chakraverty R, Rabin N, Peggs K, Robinson S, Duncan JR, Yong K. Dermatomyositis and sarcoid-like reaction associated with multiple myeloma treated effectively by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transp 2001; 27 :1215-7.
Katagiri K, Shibuya H, Takayasu S. Bacteroides fragilis pyomyositis in a patient with multiple myeloma. J Dermatol 1996; 23: 129-32.
al-Lozi MT, Pestronk A, Choksi R. A skeletal muscle-specific form of decorin is a target antigen for a serum IgM M-protein in a patient with a proximal myopathy. Neurology 1997; 49 :1650-4.
Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr opin Rheumatol 2003;15:48-54.
Durie BGM, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Eur Hematol J 2003;4:379-398.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.